AZBio Blogs
The Arizona BioIndustry is Moving Forward Faster in 2011
The Arizona BioIndustry Association has selected finalists and honorees for its annual awards gala to be held at the Sheraton Wild Horse Pass on Oct. 13. Awards to be presented include: 2011 Michael A. Cusanovich Educator of the Year, Fast Lane Company Awards, the Arizona Bioscience Company of the Year, the Jon W. McGarity Bioscience Leader of the Year Award, and the Arizona Bioscience Researcher of the Year Award.
Patrick Soon-Shiong, chairman and CEO of National LambdaRail, announced the appointment of ASU President Michael M. Crow as head of a new Chairman’s Advisory Council.Aided by a $100 million guarantee from the Chan Soon-Shiong Institute for Advanced Health to upgrade and extend its network to support big science projects, the council will help guide the new mission of National LambdaRail, the 12,000-mile-high-performance communications network linking the nation’s leading research institutions.Continue reading
Regenesis Biomedical to Participate in the AdvaMed 2011 MedTech Conference: Selected to present in the Wound Management category and serve as a panelist on Emerging Growth Companies.
Scottsdale, Arizona, September 5, 2011 — Regenesis Biomedical, Inc., a medical technology company focused on regenerative medicine, announced today that it was selected to present at the AdvaMed 2011 MedTech conference. Regenesis presents in the Wound Management category. The aim of the conference is to connect companies that have an innovative medical technology to parties interested in investing capital, partnering, or initiating strategic alliances.Continue reading
ERIC BETZ Sun Staff Reporter azdailysun.com | Monday, September 12, 2011
He was training for a marathon that he would never run.
Within weeks, he would be sitting on the hood of his Toyota on the tarmac at Flagstaff Pulliam Airport when a blonde woman walked off a Gulfstream jet and handed him a package.
“Dr. Keim, this is the anthrax,” she told him. Read more at the Arizona Daily Sun
WASHINGTON,D.C. –The medical device tax, if implemented, could cost tens of thousands of jobs, almost double the industry’s total taxes, raise the effective tax rate to among the highest in the world, and harm U.S. competiveness, according to a study released today by the Advanced Medical Technology Association (AdvaMed). The new study, “Employment Effects of the New Excise Tax on the Medical Device Industry,” by Manhattan Institute senior fellow Diana Furchtgott-Roth and Hudson Institute senior fellow Harold Furchtgott-Roth, outlines a number of economic harms likely to result from the tax.Continue reading
AZBio uses StateNet from Lexis Nexis to stay up to date on what is happening on Capitol Hill and across the 50 states. To get the latest news, delivered to your email mailbox, get your complimentary subscription at StateNet.com or read the copy on-line here.Continue reading
Thermo Fisher Scientific Inc., the world leader in serving science, announced on September 1, 2011 that it has enhanced its workflow for biomarker research and diagnostics by acquiring Tempe, Arizona based Intrinsic Bioprobes Inc., a manufacturer of unique immuno-enrichment, sample-preparation tools used in quantitative mass spectrometry. The Intrinsic Bioprobes portfolio enables Thermo Fisher to offer its worldwide life science research and clinical diagnostics customers an enhanced solution for quantitative protein biomarker detection.
By: Michael T. Hull – Managing Director, InVent Life Sciences mhull@inventls.com (Former Regional Advocate for the U.S. SBA Office of Advocacy)
The federal government proposes and finalizes approximately 4,000 new rules every year. In general approximately 800-1,000 will directly affect small business. A 2008 study by the U.S. Small Business Administration’s Office of Advocacy estimated that the cost of complying with federal rules and regulations exceeds $1.75 trillion per year with small businesses spending approximately 36% more per employee than their large business counterparts.Continue reading
TUCSON, AZ – LUCEOME BIOTECHNOLOGIES a privately held biotechnology company focused on the discovery and development of its innovative proprietary assay platform today announced the award of $1.6 million in grant funding from The National Institutes of Health to further their research in high throughput screening using the KinaseSeeker™ technology. Earlier this year, Luceome was awarded a grant for $287K for research in the area of poly(ADP-ribose) detection.
There is a lot happening on the medical device front these days around MDDS (Medical Device Data Systems) and the FDA is paying close attention with new regulations, guidance and requests for comment.
With the April 2012 compliance deadline less than 8 months away, AZBio Member John C. Hoffman of QMR is paying close attention too and keeping our community in the loop via the AZBio Resource Network Group on LinkedIn. If you and your team are working in the MDDS space, you’ll want to get connected and join the discussion.